NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
37 trialsNCT05843253 2026-03-20
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03180502 2025-07-11
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT00114140 2024-07-08
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT01466686 2023-07-03
Low Dose Radiation Therapy for Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT02023905 2022-12-29
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
University of California, San Francisco
Phase 2 Terminated
NCT01478321 2020-03-12
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Phase 2 Terminated
NCT01164189 2019-02-28
TAVAREC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02209428 2019-02-21
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Huashan Hospital
Phase 2 Unknown
NCT00313729 2019-02-07
Temozolomide in Treating Patients With Low-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT01868906 2018-08-24
FMISOPETSCS
Dr. Negrin University Hospital
Phase 2 Terminated
NCT00003176 2018-06-27
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT00362570 2017-11-30
Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00783393 2017-05-15
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00498927 2016-02-29
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006263 2015-08-05
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT01517776 2015-07-21
HGG-CilMetro
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Terminated
NCT00616005 2014-08-18
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Duke University
Phase 2 Completed
NCT00003466 2014-07-09
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00613093 2014-07-09
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Duke University
Phase 2 Completed
NCT00028795 2014-02-21
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Phase 2 Completed
NCT00492687 2014-01-10
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004204 2014-01-06
Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00575887 2013-12-20
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Marmara University
Phase 2 Completed
NCT00431561 2013-12-03
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Isarna Therapeutics GmbH
Phase 2 Completed
NCT00360945 2013-09-17
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005955 2013-06-20
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Duke University
Phase 2 Completed
NCT00004113 2013-06-19
Temozolomide in Treating Patients With Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00004068 2011-10-04
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00165360 2009-11-02
Prolonged Daily Temozolomide for Low-Grade Glioma
Dana-Farber Cancer Institute
Phase 2 Completed